SCHEMBL2829094

SCHEMBL2829094

NC(=O)c1cccc(CO)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.44
MBOAT4 Q96T53 1/20 0.44
KDM4E B2RXH2 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ACMSD Q8TDX5 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
BRD4 O60885 1/20 0.40
CCR1 P32246 1/20 0.39
HRH4 Q9H3N8 1/20 0.38
P2RX7 Q99572 1/20 0.38
ROCK2 O75116 1/20 0.38
DGAT1 O75907 1/20 0.38
CYP2C19 P33261 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6454773 0.85 PIM1 (0.42) PIM1MBOAT4KDM4EALOX15TSHR
SCHEMBL2891884 0.84 PIM1 (0.44) PIM1MBOAT4KDM4EALOX15TSHR
SCHEMBL30487682 0.84 PIM1 (0.44) PIM1MBOAT4KDM4EALOX15TSHR
SCHEMBL9356159 0.83 KDM4E (0.43) KDM4EALOX15TSHRACMSDTDP1
Hydrochloric Acid SCHEMBL30476614 0.82 PIM1 (0.43) PIM1MBOAT4KDM4EALOX15TSHR
SCHEMBL2824742 0.82 PIM1 (0.43) PIM1MBOAT4KDM4EALOX15TSHR
SCHEMBL28849815 0.82 PIM1 (0.43) PIM1MBOAT4KDM4EALOX15TSHR
Hydrochloric Acid SCHEMBL3984366 0.82 PIM1 (0.43) PIM1MBOAT4KDM4EALOX15TSHR
SCHEMBL2829475 0.82 PARP1 (0.54) PIM1MBOAT4KDM4EALOX15TSHR
SCHEMBL347912 0.82 KDM4E (0.64) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029159-A Preparation scheme of benzimidazole compound 拉夸里亚创药株式会社 2026-05-12 CN claimed
EP-1844044-B1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-07-21 EP claimed
US-7678815-B2 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
US-7482341-B2 N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-01-27 US claimed
JP-2008515826-A 2008-05-15 JP claimed
EP-1844044-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-17 EP claimed
WO-2006037501-A9 ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES HOFFMANN LA ROCHE (CH) 2007-08-02 WO claimed
EP-1799647-A1 ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2007-06-27 EP claimed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US claimed
WO-2006074884-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-07-20 WO claimed
WO-2006037501-A1 ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2006-04-13 WO claimed
US-20060074237-A1 N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors HOFFMANN-LA ROCHE INC. 2006-04-06 US claimed
CN-122029159-A Preparation scheme of benzimidazole compound 拉夸里亚创药株式会社 2026-05-12 CN disclosed
CN-113563245-B Substituted pyrrolidines and their use in medicine 广东东阳光药业股份有限公司 2024-10-15 CN disclosed
CN-116354862-A Substituted azacyclic compounds and application thereof in medicines 广东东阳光药业有限公司 2023-06-30 CN disclosed
CN-116354992-A PDE4 inhibitor and application thereof in medicines 广东东阳光药业有限公司 2023-06-30 CN disclosed
EP-0575614-A1 THIAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-12-29 EP disclosed
WO-1992016526-A1 THIAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-10-01 WO disclosed
CN-1050191-A New thiazole derivative, they the preparation method and contain their pharmaceutical composition FUJISAWA PHARMACEUTICAL CO (JP) 1991-03-27 CN disclosed
EP-0417751-A2 New thiazole derivatives, processes for the preparation thereof and pharmaceutical compositon comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074237-A1 N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors HSD3B1, HSD3B2, HSD11B2 PIM1 3477/4885MBOAT4 987/4885KDM4E 1422/4885
US-20060160857-A1 Thiazole-4-carboxyamide derivatives GRM1, GRM2, GRIA4 PIM1 3908/4885MBOAT4 1033/4885KDM4E 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.